Index

a
ABT-414 336, 370
ABV-838, 335
acute myeloid leukemia (AML) 11
ADC bioanalysis
  ADC assays in regulated studies 196–197
  antibody-conjugated payload levels 181
  anti-therapeutic antibodies 181
  assays 193–194
  biodistribution assessment 195–196
  biomeasures and biomarkers 199–200
  calculated conjugated payload determination 187–188
  calicheamicin and microtubule inhibitors 180
  cleavable linker 188–189
  custom anti-payload reagents 181
  cytotoxic payloads 181
  immunogenicity assays 194–195
  immunoprecipitation mass spectrometry 180
  intact protein bioanalysis 184–186
  LC/MS strategies 182–183
  ligand binding assays 190–191, 197–198
  nonregulated unconjugated payload 183–184
  peptide-based analysis 189–190
  pharmacokinetic bioanalysis 186–187
  potential analytes 181–182
  reagents 191–192
  reference standards 192
  regulated anti-therapeutic assays 199
  regulated conjugated payload LC/MS assays 199
  serum total antibody 181
  target interference 194
  total antibody assays 192–193
  unconjugated payload 198–199
  in vivo drug-to-antibody ratio 179–180
  Adcertis® 40, 59, 62, 245–246, 261, 347. see also brentuximab vedotin
  ADC immunogenicity assays 194–195
  ADC inotuzumab ozogamicin (CMC-544) 88
  ADC nonclinical safety assessments
    allometric scaling factor 282
    anticancer pharmaceuticals 268, 271
    carcinogenicity 272
    cytotoxic agents 269
ADC nonclinical safety assessments
(contd.)
developmental and reproductive
toxicology 280
dosing schedules 283
FDA experience 268–269
first-in-human dose
selection 280–282
first-in-human dosing 269
generalized nonclinical development
program 271
genotoxicity 280
ICH S9 Guidelines 270
ICH S6 Guidelines 272
immunohistochemistry-based tissue
cross-reactivity 271
IND application 270
late-stage clinical
development 269
monoclonal antibodies 267
pharmacokinetics/
toxicokinetics 279
pharmacology studies 278–279
phase 1 dose-escalation
studies 268
species selection 272–275
study duration and dose
regimen 275–276
study test article 276–278
ADC pharmacokinetic
bioanalysis 186–187
ADC reference standards 192
ADCs in clinical development
antibody 321, 327
clinical trial phases 321, 327
clinical use of 330
FDA approved 329–330
future of 330
hematological malignancies and
renal cell carcinoma
ABV-838 335
auristatins 330–332
calicheamicins 335
maytansinoids 332–333
milatuzumab-doxorubicin 335
pyrrolobenzodiazepines 334–335
history of 329
linker 327–328
oncology therapies 340
payload 328
phase I clinical trials 321–326
solid malignancies
auristatins 335–338
maytansinoids 338–339
MM-302 339
ADC targets
biparatopic ADCs 51
cardiomyocytes 39
cell surface antigen 39
DNA repair inhibitors 52
dose-limiting toxicities 38
endosome/lysosome system 39
immunomodulatory cancer
drugs 52
indication-dependent selection
(see indication-dependent
ADC target selection)
indication-independent selection
(see indication-independent
ADC target selection)
internalization and lysosomal
localization 36–37
lifastuzumab vedotin 37–38
MMAE 38
mRNA expression profiles 36
myth vs. reality 36
PF-06263507 38
polyspecific ADCs 51
posttranscriptional regulatory
mechanisms 36
protein expression 36
safety studies 51
trastuzumab 38
trastuzumab emtansine 37
tubulin inhibitors 39
tumor-associated antigens 35
<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ado-trastuzumab emtansine (T-DM1)</td>
<td>14–15, 19, 207</td>
</tr>
<tr>
<td>see also trastuzumab emtansine (T-DM1)</td>
<td></td>
</tr>
<tr>
<td>pharmacokinetics</td>
<td>259</td>
</tr>
<tr>
<td>adozelesin</td>
<td>10–11</td>
</tr>
<tr>
<td>AETHERA study</td>
<td>392, 400</td>
</tr>
<tr>
<td>AGS-16</td>
<td>292</td>
</tr>
<tr>
<td>AGS-16C3F</td>
<td>338</td>
</tr>
<tr>
<td>Ags67e</td>
<td>331</td>
</tr>
<tr>
<td>ALCANZA trial</td>
<td>398</td>
</tr>
<tr>
<td>AlexaFluor488</td>
<td>96</td>
</tr>
<tr>
<td>amatoxins</td>
<td>478–479</td>
</tr>
<tr>
<td>AMG 172</td>
<td>339</td>
</tr>
<tr>
<td>AMG 595</td>
<td>339</td>
</tr>
<tr>
<td>anaplastic large-cell lymphoma (ALCL) cells</td>
<td>381</td>
</tr>
<tr>
<td>anetumab ravtansine (BAY 94–9343)</td>
<td>339</td>
</tr>
<tr>
<td>anthracyclines</td>
<td>477–478</td>
</tr>
<tr>
<td>antibodies</td>
<td>156, 482</td>
</tr>
<tr>
<td>alternative formats and masked antibodies</td>
<td>488–489</td>
</tr>
<tr>
<td>beyond oncology</td>
<td>489–491</td>
</tr>
<tr>
<td>engineered cysteines</td>
<td>483–484</td>
</tr>
<tr>
<td>enzyme-assisted conjugation</td>
<td>484–487</td>
</tr>
<tr>
<td>non-native amino acids and selenocysteine</td>
<td>487–488</td>
</tr>
<tr>
<td>occupational health and safety aspects</td>
<td>156</td>
</tr>
<tr>
<td>antibody-conjugated drug</td>
<td>254</td>
</tr>
<tr>
<td>antibody-conjugated MMAE (ac-MMAE)</td>
<td>309</td>
</tr>
<tr>
<td>antibody-conjugated payload levels</td>
<td>181</td>
</tr>
<tr>
<td>antibody-dependent cell-mediated cytotoxicity (ADCC)</td>
<td>385</td>
</tr>
<tr>
<td>antibody-dependent cellular cytotoxicity (ADCC)</td>
<td>8, 140–141</td>
</tr>
<tr>
<td>antibody-dependent cellular phagocytosis (ADCP)</td>
<td>141</td>
</tr>
<tr>
<td>antibody-drug conjugate (ADC)</td>
<td></td>
</tr>
<tr>
<td>antibody isotype</td>
<td>7–8</td>
</tr>
<tr>
<td>antitumor activity</td>
<td>24</td>
</tr>
<tr>
<td>biochemical and microbiological testing</td>
<td>74</td>
</tr>
<tr>
<td>brentuximab vedotin</td>
<td>24</td>
</tr>
<tr>
<td>clinical development</td>
<td>287–290</td>
</tr>
<tr>
<td>clinical pharmacology</td>
<td></td>
</tr>
<tr>
<td>considerations</td>
<td>301</td>
</tr>
<tr>
<td>comparability</td>
<td>76</td>
</tr>
<tr>
<td>components and mechanism of action</td>
<td></td>
</tr>
<tr>
<td>conjugation</td>
<td></td>
</tr>
<tr>
<td>ICH Q6B</td>
<td>62</td>
</tr>
<tr>
<td>linker design</td>
<td>65–66</td>
</tr>
<tr>
<td>lysine and cysteine conjugation</td>
<td>63</td>
</tr>
<tr>
<td>novel payloads</td>
<td>64–65</td>
</tr>
<tr>
<td>physical and chemical forces</td>
<td>63</td>
</tr>
<tr>
<td>storage, handling, and quality of reagents</td>
<td>64</td>
</tr>
<tr>
<td>succinimidyl functionality</td>
<td>62</td>
</tr>
<tr>
<td>thiol-based conjugation</td>
<td>62</td>
</tr>
<tr>
<td>unconjugated gemtuzumab</td>
<td>64</td>
</tr>
<tr>
<td>critical quality attributes</td>
<td>60–61</td>
</tr>
<tr>
<td>cysteine residues</td>
<td>17–19</td>
</tr>
<tr>
<td>cytotoxic compounds</td>
<td>10</td>
</tr>
<tr>
<td>design of phase 1 studies</td>
<td>293</td>
</tr>
<tr>
<td>from discovery into early clinical development</td>
<td>292–293</td>
</tr>
<tr>
<td>DNA-targeting payloads</td>
<td>11</td>
</tr>
<tr>
<td>dosing regimen</td>
<td></td>
</tr>
<tr>
<td>optimization</td>
<td>296–297</td>
</tr>
<tr>
<td>dosing strategy</td>
<td></td>
</tr>
<tr>
<td>considerations</td>
<td>294–296</td>
</tr>
<tr>
<td>doxorubicin</td>
<td>5</td>
</tr>
<tr>
<td>drug-drug interaction</td>
<td></td>
</tr>
<tr>
<td>assessments</td>
<td>302–303</td>
</tr>
<tr>
<td>efficacious dose range</td>
<td>218–220</td>
</tr>
<tr>
<td>extended characterization</td>
<td>74–75</td>
</tr>
<tr>
<td>first-in-human starting dose</td>
<td></td>
</tr>
<tr>
<td>estimation</td>
<td>293–294</td>
</tr>
<tr>
<td>formulation</td>
<td>68–70</td>
</tr>
</tbody>
</table>
antibody-drug conjugate (ADC) (contd.)
functional activity of antibody moiety 8–9
general manufacturing process 60
hydrophilic antibody protein 3
immunogenicity 303
linker chemistries 12–14
lysine residues 13–17
mAb engineering 66–67
monoclonal antibody 59
organ impairment
assessments 301–302
payloads targeting tubulin 10–12
pharmacokinetics 23–24
pharmacometric strategies 307–308
phase 1 study design 297–299
physiologically based pharmacokinetic and quantitative systems pharmacology models 308–311
potent anticancer compounds 4
product development 59
purification 68
QT/QTc assessments 303, 306–307
quality and stability testing
chemical and physicochemical degradation pathways 70–71
dynamic light scattering 73
hydrophobic interaction chromatography 73
imaging capillary isoelectric focusing 73
ion exchange chromatography 73
multi-angle light scattering 72
product development and characterization 70
residual solvents 74
reverse-phase HPLC 74
size exclusion chromatography 71
solution-based chromatographic and electrophoretic methods 71
quality target product profile 62
structural attributes 19–20
supportive strategies 299–301, 304–306
therapeutic index 3–4
therapeutic indications 291–292
vinca alkaloids 5
in vitro properties 20–21
in vivo efficacy 20–23
antibody isotype 7–8
anti-CanAg antibody 7
anti-CD11a-LXR agonist ADC 490–491
anti-CD19 antibody 7
anti-CD30 antibody 43
anti-CD79b-vcMMAE 397
anti-CD22 mAb 138
anti-CD30 monoclonal antibodies 292
anti-CD22-NMS249 478
anti-CD30-val-cit-PABC-MMAE ADC 87
anti-Cripto antigen 292
antidrug antibody (ADA) 279
antifolate receptor alpha (anti-FRα) antibody 7
antigen and antibody-drug conjugate internalization 211–212
antigen binding assays 137–139
antigen-binding potency 74
antigen density 211
anti-HER2 antibody trastuzumab 40
anti-idiotypic mAbs 143
antiproduct antibodies (APA) 143
anti-therapeutic antibodies (ATAs) 248
anti-therapeutic assays 199
ASG-22CE 336
ASG-15ME 336
Asn-297 486
auristatins 17, 47
hematological malignancies and renal cell carcinoma 330–332 solid malignancies 335–338 autologous stem cell transplantation (ASCT) 382
Av integrin 292

bacterial transglutaminase (BTG) 92
β-arylethylamine-drug ligand 91
basiliximab 417
benzodiazepine dimers 474, 476–477
Bexar 446
bicyclononyne (BCN) 93
biodistribution assessment, ADC 195–196 biomarker assays 216
brentuximab vedotin 13, 18, 209
ALCANZA trial 398
anaplastic large-cell lymphoma 382–383
anaplastic lymphoma kinase gene 382–383
antitumor activity 387
CD30 expression level and response to BV 393–394
CD30 with monoclonal antibodies 383–386
clinical context 394–395
ECHELON-1 399
ECHELON-2 397
efficacy 391–393
FDA approval 382
Hodgkin’s lymphoma 382
Karpas 299 387
localized ALCL xenograft model 387
mechanism of action 386–387
mechanisms of resistance 395–397
ongoing clinical trials 397–398
pharmacokinetics 261

rituximab 381
safety/tolerability 388–391
T-cell prolymphocytic leukemia 398
valine-citrulline linkage 387
bromoacetamidecaproyl-monomethyl auristatin F (bac-MMAF) 114
bystander effect 155

CA6 292
calicheamicin 11, 38, 269, 297, 335
camptothecin analog SN38 11
CanAng 292
Cancer Cell Line Encyclopedia (CCLE) 44
cancer stem cells (CSCs) 48
cantuzumab 7
carbonic anhydrase 292
carbonic anhydrase IX (CAIX, G250) 455
carcinoembryonic antigen (CEA) 409, 418–419, 441
caspase-cleaved cytokeratin 18 (ccCK18) 216
Caspase-Glo® 3/7 assay 139
cathepsin B 189
cathepsin B lysosomal protease 86
cathepsin B-sensitive linkers 87
CD19 292
CD20 412–415
CD22 291–292, 416
CD25 416–417
CD30 291, 381
CD33 291, 417
CD56 292
CD70 292
CD74 292
CD138 292
CD79b 50
CD30-targeted mAb therapy 386
CEACAM5 292
cell-based binding assays 138
cell-based cytotoxicity assays 139–140
cell line testing 210–211
antigen and antibody-drug conjugate internalization 211–212
antigen density 211
payload processing and binding 213–214
CellTiter-Fluor™ kit 140
cell viability assays 139
Center of Drug Evaluation and Research (CDER) 268
chemical protective clothing
eye and face protection 168
gloves 167–168
protective clothing 167
chemical stability, ADCs
auristatin payload–linkers 112
bromoacetamidecaproyl-monomethyl auristatin F 114
cBR96-AEVB 112
cBR96 conjugates 112
cleavable linkers 111
dipeptide-linked conjugates 113
gemtuzumab ozogamicin conjugate 113
hydrazine linker conjugates 114
maleimidocaproyl-monomethyl auristatin F 114
maytansinoid payload analogs 113
noncleavable linkers 111
protein chemical liabilities 111
thioether-succinimide linkage 113
Val-Cit peptide 113
chiHEA125-ama ADC 479
chimeric antibodies 6
cleavable linkers 188–189
vs. noncleavable linkers 88–89
and self-immolative groups 86–88
clinical pharmacology and pharmacokinetics,
T-DM1 361–362
clinical pharmacology considerations,
ADCs 301
clivatuzumab 419
coltuximab 7
coltuximab ravtansine 19
complement-dependent cytotoxicity (CDC) 141
conjugated antibody 254
conjugated payload LC/MS assays 199
conjugation
ICH Q6B 62
linker design 65–66
lysine and cysteine conjugation 63
novel payloads 64–65
physical and chemical forces 63
storage, handling, and quality of reagents 64
succinimidyl functionality 62
thiol-based conjugation 62
unconjugated gemtuzumab 64
$^{64}$Cu 449–451
$^{64}$Cu-DOTA-trastuzumab 449
custom anti-payload reagents 181
cysteine-linked ADCs 134–135
cysteine-rebrided ADCs 480
cysteine residues, conjugation of payloads to antibodies 17–19
cytochrome P450 3A4 (CYP3A4) 309
cytochrome P450 drug-metabolizing enzymes 302
cytokeratin 18 (CK18) 216
cytotoxic compounds,
structures of 10
cytotoxic drug 253–254
cytotoxic payloads 181
cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) antibodies 230
d
dasatinib 490
diethylene triamine pentaacetic acid (DTPA) 412
Index

diffuse large B-cell lymphoma (DLBCL) 393
dipeptide-linked conjugates 113
disulfide rebridging 479–481
di-thiopyridylmaleimide (DTM) 91
DNA-damaging agents 209
DNA-targeting payloads 11
dose-escalation methods 298
dose-limiting toxicity (DLT) criteria 297
dosimetry, for radioimmunotherapy 445–447
dosing regimen optimization 296–297
dosing strategy considerations 294–296
doxorubicin 5, 269
doxorubicin propyloxazoline (DPO) cytotoxins 90
drug-drug interaction assessments 302–303
drug-induced pancreatitis 391
drug loading distribution 133–134
cysteine-linked ADCs 134–135
lysine-linked ADCs 134
drug-related substances 137
drug-to-antibody ratio (DAR) 45, 67, 132–133, 184–186
duocarmycin 11, 87

glucosyltransferases and glycan engineering 486–487
microbial transglutaminase 484–485
enzyme-cleavable linkers 189
enzyme-linked immunosorbent assay (ELISA) 97, 254
epidermal growth factor receptor (EGFR) 445
ethylvinyl acetate (EVA) 124
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) 368

f

Fc-dependent effector functions 140–142
FDA approved ADCs 329–330
first-in-human (FIH) dose selection 217, 280–282
first-in-human starting dose estimation 293–294
5T4 292
5T4-calicheamicin ADC 38
Fleximer technology 90
Fleximer™ polymeric linkers 481–482
formulation and stability, ADCs ado-trastuzumab emtansine 122
aggregation mechanism 115
arginine-containing solutions 118
brentuximab vedotin 122
chemical stability 111–114
commercially available ADCs 115–116
conjugation approach 117
cytotoxic agents 120
design process 105
development 105
diluent and dilution factor 122
drug load fractions 118–119
formulation and stability, ADCs  
(contd.)
formation of interchain cross-links  120
health care professionals  123
ionic strength  117
logistical considerations  123–125
lyophilized products  121
melting temperature  118–119
monoclonal antibody  115
N-acetylated amino acids  120–121
physical and chemical degradation pathways  105
physical stability  106–111
self-association  115
solubility  115
target doses  121–122
thermal stability  117
trastuzumab  120
formylglycine-generating enzyme (FGE)  91, 485–486
40-kDa type II membrane-associated glycoprotein  383
FRα-positive Ovcar-3 cell line  22
Functional Assessment of Cancer Therapy–Breast (FACT-B)  367

G

$^{68}$Ga  448–449
gadolinium-enhanced dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)  435
GATSBY  372–373
gemtuzumab ozogamicin (GO)  113, 209, 385
generic tAb assays  193
genotoxicity  280
glembatumumab vedotin  337
glucosyltransferases and other glycan engineering  486–487
GlycoConnect  93

GPNMB  292
granulocyte colony-stimulating factor (GCSF)  390
GSK2857916  331

h
hematological malignancies and renal cell carcinoma
ABV-838  335
auristatins  330–332
calicheamicins  335
maytansinoids  332–333
milatuzumab-doxorubicin  335
pyrrolobenzodiazepines  334–335
hematologic malignancies  412–415
Herceptin®  348
high-density polyethylene (HDPE)  125
highest nonseverely toxic dose (HNSTD)  293
Hsp90 inhibitor  452
human antmouse antibodies (HAMA)  415
human equivalent dose (HED)  293
human(ized) IgG1 antibody  15
hydrazone-linked ADC milatuzumab-doxorubicin  87
hydrazone linker conjugates  114
HyHEL-10 (H10) antibody  107

i

$^{124}$I  454–456
$^{125}$I-and $^{131}$I-labeled anti-A33 antibody  455
ICH S7A  278
ICH S9 and ICH S6(R1) Guidelines  272
ICH S7B  278
IgG1 scaffolds  107
IgG1 scaffolds  107
immunogenicity, ADCs  303
immunogenicity assays  142–144
immunohistochemistry-based tissue cross-reactivity (TCR) study  271
Index

\[ \text{In-bevacizumab} \] 447
\[ \text{IncuCyte ZOOM} \] 140
indication-dependent ADC target selection
auristatins 47
brentuximab vedotin 43
cancer stem cells 48
CD30 43
clinical development 40–43
DNA-targeting agents 46
drug-to-antibody ratio 45
genetic profiling studies 44
hematological malignancies 48
hematological targets 47
HER2 overexpression 40
maytansinoids 47
microtubule inhibitors 46
off-target effects 47
quantitative proteomic approaches 44
target expression patterns 44–45
target expression profiling 46
trastuzumab emtansine 40
indication-independent ADC target selection 48
CD74 49–50
cell surface localization 49
lymphocyte antigen 6 complex locus E 50
milatuzumab-Dox 50
phenotypic screening 49
polatuzumab vedotin 50
indolino-benzodiazepine (IGN) dimers 476
indusatumab vedotin (MLN0264) 336
industrial hygiene
monitoring 169–170
air monitoring 170
surface monitoring 170–171
\[ \text{In-igovomab} \] 441
inotuzumab ozogamicin 209
\[ \text{In satumomab pendetide} \] 443, 458
intact protein bioanalysis 184–186
International Conference of Harmonisation (ICH) Guidelines 268
International Consortium for Innovation and Quality in Pharmaceutical Development 257
Investigational New Drug (IND) applications
antibody-drug conjugate efficacious dose range 218–220
anticipated human efficacious dose 217
first-in-human dose selection 217
pharmacological activity 216
safety assessments 217
\[ \text{I-PEG-AVP0458} \] 455
irinotecan SN-38 (2 NMEs) 269
\[ \text{I-tositumomab} \] 412–413
\[ \text{Kadcyla} \] 37, 59, 62. see also trastuzumab emtansine (T-DM1)
Karpas 299 387
KARPAS 299R 396
\[ \text{l} \]
lapatinib 346
LC/MS/MS quantitation of unconjugated payload 198–199
leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) 229
leukemias 417
Lewis y 292
lifastuzumab vedotin 37–38
ligand binding assays
non-regulated ADC pharmacokinetic and immunogenicity 190–191
regulated ADC pharmacokinetics and immunogenicity evaluation 197–198
linker and conjugation technology 96–98
analytical methods 96–98
antigen-mediated internalization 85
cleavable linkers and self-immolative groups 86–88
cleavable vs. noncleavable linkers 88–89
drug resistance 94–96
magic bullets 98
next-generation linker technologies 89–91
pharmacokinetics and ADME 93
polyethylene glycol 93–94
site-specific conjugation, homogeneous drug species, and therapeutic window 91–93
solid tumor penetration 96
linker chemistries 12–14
linker technologies 154–156
localized ALCL xenograft model 387
lorvotuzumab mertansine (IMGN901) 338
low-density polyethylene (LDPE) 124
Lym-1 (anti-HLA-DR10 antibody) 415–416
lymphocyte antigen 6 complex locus E (LY6E) 50
lymphomas 415–417
lysine-linked ADCs 134
lysine residues, conjugation of payloads to antibodies
ado-trastuzumab emtansine 14–15
deconvoluted mass spectra 16
human(ized) IgG1 antibody 15
maytansinoid-to-antibody molar ratio 15
N-hydroxysuccinimide esters 13
pharmacokinetic properties 13
mAb engineering 66–67
maleimidocaproyl (MC) linker 86
maleimidocaproyl-monomethyl auristatin F (mc-MMAF) 114
maleimidomethyl cyclohexane-1-carboxylate (MCC) linker 86
malignant Hodgkin Reed–Sternberg cell 381
masked antibodies 488–489
material handling, ADC activities
comprehensive program 161
facility-handling payloads 161
handling of powders 162–163
handling of solutions 162–163
specific chemical risk assessment 160
written procedures 161
maytansine 153
maytansinoids 47
hematological malignancies and renal cell carcinoma
332–333
payloads 95
solid malignancies 338–339
MDX-060 385
medical surveillance program, ADCs 171–172
mesothelin 292
microbial transglutaminase 67, 484–485
microtubule-binding agents 209
microtubule inhibitor monomethyl auristatin E (MMAE) 38
microtubule inhibitors (MTIs) 46, 474, 476
milatuzumab-doxorubicin (hLL1-dox, IMMU-110) 335
mirvetuximab 7
mirvetuximab soravtansine 8, 22
MM-302 (HER2-tPLD) 339
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 44
monoclonal antibodies  4
mono-imine IGN anti-CD33  ADC  476–477
monomethyl auristatin F (MMAF)  138
mononuclear phagocytic system (MPS)  94
murine antibodies  6
murine monoclonal antibody (AC10)  384
mycosis fungoides (MF)  393
myelosuppression  308
Mylotarg®  64, 245, 347
n  “naked” antibody  19
NCI-N87 gastric xenograft model  372
Nectin-4  292
neonatal Fc receptor (FcRn)  208
neonatal Fc receptor (FcRn)-dependent recycling  246
neutralizing antibody (NAB) assays  191
next-generation ADC technologies antibodies  482
alternative formats and masked antibodies  488–489
beyond oncology  489–491 engineered cysteines  483–484
enzyme-assisted conjugation  484–487
non-native amino acids and selenocysteine  487–488
emerging ADC technologies and exemplary constructs  474–475
novel cytotoxic payloads and linkers
amatoxins  478–479
anthracyclines  477–478
benzodiazepine dimers  474, 476–477
disulfide rebridging  479–481

Fleximer™ polymeric linkers  481–482
microtubule inhibitors  474, 476
technology innovations  473
90Y-clivatuzumab tetraxetan (90Y-hPAM4)  420
90Y-DOTA-panitumumab  419
90Y-hMN-14-anti-CEA  421
90Y-ibritumomab tiuxetan  414, 420
N-maleimidomethyl cyclohexane-1-carboxylate  347
noncleavable linkers  86
nonclinical pharmacology and mechanistic modeling
ado-trastuzumab emtansine  207
antibody-drug conjugate pharmacology  227–228
antigen-dependent and antigen-independent toxicities  210
cell line testing  210–211
antigen and antibody-drug conjugate internalization  211–212
antigen density  211
payload processing and binding  213–214
cleavable linkers  209
considerations for nonclinical testing  229–230
DNA-damaging agents  209
dose limitations  210
enhanced pharmacokinetic modeling  226–227
IND applications
antibody-drug conjugate efficacious dose range  218–220
anticipated human efficacious dose  217
first-in-human dose selection  217
pharmacological activity  216
safety assessments  217
nonclinical pharmacology and mechanistic modeling (contd.)
mechanism of action 207–208
microtubule-binding agents 209
neonatal Fc receptor 208
noncleavable linkers 209
pH-dependent electrostatic binding 208
quantitative systems pharmacology 221
shed antigen and endosomal processing 225–226
subcellular trafficking 225
target-mediated toxicity 228–229
tumor tissue transport considerations 221–225
xenograft models biomarker assays 216
nonhuman primates 214
payload bystander effects 215–216
PDXs 214
non-native amino acids and selenocysteine 487–488
non-regulated ADC pharmacokinetic and immunogenicity assays 193–194
ligand binding assays 190–191
reagents 191–192
reference standards 192
total antibody assays 192–193
nonregulated unconjugated payload bioanalysis 183–184
Norton–Simon hypothesis 296
novel cytotoxic payloads and linkers amatoxins 478–479
anthracyclines 477–478
benzodiazepine dimers 474, 476–477
disulfide rebridging 479–481
Fleximer™ polymeric linkers 481–482
microtubule inhibitors 474, 476
N-succinimido 4-[(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker 86

occupational exposure limit (OEL) 157
occupational health and safety aspects, ADCs
air changes and airflow 164
air monitoring 170
antibodies 156
binding efficiency 159
cell surface targets 153
changing areas 164–165
cleaning 167
components of typical ADC molecule 152
conjugation 166
designated areas 165
eye and face protection 168
facility-handling payloads 161
free payload in conjugation formulation 160
gloves 167–168
handling of powders 162–163
handling of solutions 162–163
HVAC and air pressure relationships 164
linker technologies 154–156
local effects in lung 160
lyophilization 166–167
medical surveillance program 171–172
occupational hazard assessment 157–158
partial conjugates 156
payloads 153–154
payload synthesis 165–166
potent compound awareness training 169
protective clothing 167
recirculation and filtration of room air 164
respiratory protection 168
routes of occupational exposure 159
standard operating procedures 169
standard risk assessment methodologies 151
surface monitoring 170–171
unintended targets 160
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 412
organ impairment assessments, ADCs 301–302
OSHA’s Hazard Communication Standard 168
Oxford Genome Anatomy Project (OGAP) 50

p
pancanceroma antigen 443–444
partial conjugates 156
patient-derived xenograft (PDX) models 21, 209
payload bystander effects 215–216
payload processing and binding 213–214
pentumomab 419
peptide-based analysis 189–190
peripheral neuropathy 390
permeability glycoprotein (PgP) 95
personal protective equipment
   chemical protective clothing 167–168
   respiratory protection 168
pertuzumab 346, 445
PF-06263507 38
P-glycoprotein 213
pharmacokinetics 23–24
   acute myeloid leukemia 245
   ADC biodistribution 248–249
   ADC clearance 249–250
   ado-trastuzumab emtansine 259
antibody component 246
bioanalytical methods 254–255
brentuximab vedotin 261
CD33-targeted antibody 245
characteristics to small molecule and mAb 246–247
cytotoxic drug 253–254
design optimization 257–258
exposure–response relationship 246
immunogenicity 248
linker stability 250–251
maytansinoid derivative 246
mean parameters 259–260
pharmacokinetic/pharmacodynamic models 256–257
pinocytosis 247
receptor-mediated endocytosis 247
site of conjugation and drug load 252–253
toxicokinetics 279
   in vitro assays 255–256
   in vivo studies 256
pharmacology studies 278–279
pharmacometric strategies, ADCs 307–308
phenotypic screening 49
physical stability, ADCs
   amine-coupled ADCs 107
   anti-6xHis antibody 107
   biotin load 107
   CH2 domain 109
coupling of payload-linkers 106
   DAR 8 fragmentation 110
drug DM1 108
formation of aggregates 108–109
   IgG1 scaffolds 107
ionic strength buffer 108, 110
   partially buried lysines 106
steric hindrance 106
   structural perturbation 110
surface properties 106
physical stability, ADCs (contd.)
time-and DAR-dependent fragment formation 110–111
trastuzumab 108
physiologically based pharmacokinetic and quantitative systems pharmacology models 308–311
physiologically based pharmacokinetic (PBPK) model 301
PI3K/AKT signaling pathway 370
PNU159682 229
copolycarbonate 125
polyethylene glycol (PEG) linkers 93–94
spacers 66
poly-1-hydroxymethylethylene hydroxymethyl formal (PHF) 90
polytetrafluoroethylene (PTFE) 125
polytherics 481
positional isomers 136
positron emission tomography (PET) 64
68Ga 448–449
124I 454–456
89Zr 451–454
potent anticancer compounds 4
potent compound awareness training 169
potent tumor cell-killing mechanism 6
Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 270
Probody™ technology 489
prostate-specific membrane antigen (PSMA) 441–443
PSMA 292
pyridazinedione (PD) linker 96
pyrrolobenzodiazepine (PBD) dimers 11, 269, 474, 476
pyrrolobenzodiazepines (PBDs) 64, 334–335
q
QC assay development
ADC concentration 136
antigen binding assays 137–139
assays designed for ADCs 131–132
cell-based cytotoxicity assays 139–140
cysteine-linked ADCs 134–135
drug-related substances 137
drug-to-antibody ratio 132–133
Fc-dependent effector functions 140–142
immunogenicity assays 142–144
impurity profile analysis 144
lysine-linked ADCs 134
monoclonal antibody 131
positional isomers 136
quality and stability testing, ADCs
chemical and physicochemical degradation pathways 70–71
dynamic light scattering 73
hydrophobic interaction chromatography 73
imaging capillary isoelectric focusing 73
ion exchange chromatography 73
multi-angle light scattering 72
product development and characterization 70
residual solvents 74
reverse-phase HPLC 74
size exclusion chromatography 71
solution-based chromatographic and electrophoretic methods 71
quality target product profile (QTPP) 62
quantitative systems pharmacology (QSP) models 221
radioactive thymidine/5-bromo-2’-deoxyuridine (BrdU) 139
radioimmunotherapy (RIT)
  administration 422
  bevacizumab 423
  chemistry 411–412
  chemotherapy 420–421
cyclosporine A 422
EBRT and chemotheraphy 421–422
external beam radiation treatment 421
hematologic malignancies 412–415
  history of 409–410
  leukemias 417
  lymphomas 415–417
radioisotopes 410–411
solid tumors 417–418
  carcinoembryonic antigen 418–419
  clivatuzumab 419
  90Y-DOTA-panitumumab 419
  pemtumomab 419
  trastuzumab 419
  211At-labeled trastuzumab 419–420
radioisotopes 410–411
radiolabeled antibody-based imaging, oncology
  antibodies as imaging agents
    cold antibody 438
    engineered antibody formats 436
    high tissue signal 436
  111In-labelled hCTM01 439
  radiolabeled tracers 437
  radionuclides 436
  shorter-lived radionuclides 437
  signal-to-background ratio 435
stable labeling method 435
  applications 434–435
clinical benefit 462
commercialization considerations 456–460
PET
  $^{64}$Cu 449–451
  $^{68}$Ga 448–449
  $^{124}$I 454–456
  $^{89}$Zr 451–454
scintigraphy and SPECT advantages 439
antibody imaging agents 440
CEA 441
dosimetry for radioimmunotherapy 445–447
early assessment of response 447
EGFR 445
HER2 444–445
  $^{111}$In-based imaging 440
  pancarcinoma antigen 443–444
  PSMA 441–443
  TAG-72 443
  $^{99m}$Tc-based imaging agents 440
  technetium 439
radretumab 455
REDECTANE® 455
regulated ADC pharmacokinetics and immunogenicity evaluation assays 196–197
biomeasures and biomarkers 199–200
  ligand binding assays 197–198
regulated anti-therapeutic assays 199
regulated conjugated payload LC/MS assays 199
regulated LC/MS/MS quantitation of unconjugated payload 198–199
resazurin 140
rituximab 291, 381
S
SAR3419  153, 332, 333
scintigraphy and SPECT, ADCs
  advantages  439
  antibody imaging agents  440
CEA  441
dosimetry for
  radioimmunotherapy  445–447
eyear assessment of
  response  447
EGFR  445
HER2  444–445
  $^{111}$In-based imaging  440
  pancarcinoma antigen  443–444
PSMA  441–443
TAG-72  443
$^{99m}$Tc-based imaging agents  440
technetium  439
seco-DUBA  87
Sezary syndrome  393
SGN-75  332
SGN-CD19A  331–332
SGN-CD33A  334–335
SGN-CD70A  334
SGN-LIV1A  337
shed antigen and endosomal
  processing  225–226
Simcyp Population-Based
  Simulator  309
single-agent vinblastine  394
SJG-136  10–11
SLC44A4  292
small immunoprotein (SIP)  488
SMARTag  91
SN-38 payload-linked ADCs  90
solid malignancies
  auristatins  335–338
  maytansinoids  338–339
  MM-302  339
  “stand-alone” bifunctional
    reagents  13
subcellular trafficking  225
succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC)  347
SYD-985  87
SynAffix  486

$t$
tangential flow filtration (TFF)  68
target-mediated toxicity,
  ADCs  228–229
$^{99m}$Tc-murine anti-melanoma
  fragments  441
$^{99m}$Tc nofetumomab merpentan  443
$^{99m}$Tc-votumumab  441
TENB2  292
The Cancer Genome Atlas
  (TCGA)  44
THIOMAB-MUC16-MMAE  92
THIOMAB® drugconjugated
  antibodies  226
THIOMABs  483
THIOMAB® technology  252
THIOMAB-
  trastuzumab-DM1 ADC  92
thio-trastuzumab-MC-VC-MMAE
  THIOMABs  252
TH3RESA trial  367–368
total antibody (tAb)  192–193, 254
traceless linkers  13
trastuzumab  419
trastuzumab-Dolaflexin ADC  90
traztuzumab emtansine
  (T-DM1)  37, 338
antitumor efficacy  348, 350
clinical pharmacology and
  pharmacokinetics  361–362
conjugated antibody  351
cyotoxic agent  346
disulfide-linked conjugate  349
disulfide linkers  348
dose-limiting toxicities  357
dosing schedule  359
GATSBY  372–373
HER2 345
HER2-directed therapy 372
HER2 overexpression 371
HER2-positive breast tumor model 348
HER2-positive SK-BR-3 and BT-474 cells 351
HER2 protein expression 373
humanized monoclonal antibody 346
MARIANNE 371
maytansine 347, 357
nonclinical toxicity 352–356
pharmacokinetic analyses 351
phase I adverse events 357–358
phase I efficacy 358–359
phase III trials 362–363
biomarkers 369–371
EMILIA trial 363–367
TH3RESA trial 367–368
treatment exposure 369
phase II trials 359–361
PIK3CA mutation status 374
PI3K signaling 352
p95HER2 352
preclinical safety profiles 352
preclinical studies 372
structure of 347
thioether-linked conjugate 349
thrombocytopenia 374
trastuzumab-SPDP-DM1 251
Trial Outcome Index Physical/Functional/Breast (TOI-PFB) 367
tubulin 10–12
tubulysins 474
tumor-associated glycoprotein (TAG)-72 antigen 443
tumor necrosis factor (TNF) 381
tumor tissue transport considerations 221–225
211At-labeled trastuzumab 419–420
2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cycloododecane (TCMC) 412
unconjugated drug 254
US Food and Drug Administration (FDA) 287
Val-Cit-PABC linker 189
Val-Cit peptide 113
valine-citrulline (val-cit) dipeptide linker 86
vascular endothelial growth factor (VEGF)-A 452
vinca alkaloids 5
xenograft models
biomarker assays 216
nonhuman primates 214
payload bystander effects 215–216
PDXs 214
Y90 411
Y90-ibritumomab tiuxetan 412
90Y-rituximab 451
Zevalin 446
89Zr 451–454
89Zr-cetuximab 454
89Zr-DFO-MSTP2109A 454
89Zr-GC1008 454
89Zr-labeled anti-mesothelin antibody 454
89Zr-RG7116 454
89Zr-trastuzumab 452–453